Executive Summary
Replimune Group’s QQ2 2025 results reflect a late-stage clinical oncology biotech in a heavy R&D phase, with no reported quarterly revenue and a substantial operating loss driven by research and development and ongoing trial activity. The quarter records a net loss of $53.1 million and an EBITDA of $(58.9) million, underscoring the company’s continued commitment to advancing RP1, RP2, and RP3 despite near-term profitability headwinds. The company closed the quarter with a cash balance of approximately $115.2 million and a robust liquidity profile, supported by a larger consolidated cash and short-term investments position (~$432.1 million) and a net cash position of roughly $(37.4) million, which provides runway into 2026 assuming current burn rates.
Key Performance Indicators
Key Insights
Revenue: Not disclosed for QQ2 2025 (reported as null in the quarter); Gross Profit: Not disclosed; Operating Income: $(58.9) million with YoY improvement of 7.70% but QoQ decline of 2.70%; Net Income: $(53.1) million, YoY change reported as +11.64% and QoQ +1.33%; EPS: $(0.68) per share, YoY +24.44% and QoQ +12.82%; R&D Expense: $43.448 million; SG&A / Selling, General & Administrative: $15.468 million; Other (negative) expense: $(0.229) million; Interest: $1.969 million; D&A: $...
Financial Highlights
Revenue: Not disclosed for QQ2 2025 (reported as null in the quarter); Gross Profit: Not disclosed; Operating Income: $(58.9) million with YoY improvement of 7.70% but QoQ decline of 2.70%; Net Income: $(53.1) million, YoY change reported as +11.64% and QoQ +1.33%; EPS: $(0.68) per share, YoY +24.44% and QoQ +12.82%; R&D Expense: $43.448 million; SG&A / Selling, General & Administrative: $15.468 million; Other (negative) expense: $(0.229) million; Interest: $1.969 million; D&A: $0.825 million; Net cash from operating activities: $(38.639) million; Free cash flow: $(40.723) million; Cash at end of period: $115.199 million; Total assets: $498.202 million; Total liabilities: $116.743 million; Total stockholders’ equity: $381.459 million; Current ratio: 10.11; Debt to total capitalization: 16.6%; Net debt: $(37.37) million.
Income Statement
| Metric |
Value |
YoY Change |
QoQ Change |
| Operating Income |
-58.92M |
7.70% |
-2.70% |
| Net Income |
-53.06M |
11.64% |
1.33% |
| EPS |
-0.68 |
24.44% |
12.82% |
Key Financial Ratios
operatingCashFlowPerShare
$-0.49
freeCashFlowPerShare
$-0.52
Management Commentary
Transcript data not provided in the current dataset. No management quotes or call highlights are available from the QQ2 2025 earnings call within the supplied material.
Forward Guidance
No explicit quarterly or annual guidance was presented in the provided data for QQ2 2025. Given the early-stage clinical portfolio (RP1 in Phase III for solid tumors, RP2 in Phase I, RP3 in Phase I), the company’s near-term focus remains on clinical development milestones and regulatory interactions. Investors should monitor: (1) RP1 Phase III readouts or pivotal trial progress and any safety signals; (2) RP2 and RP3 development updates and any potential partnering discussions; (3) cash runway and anticipated financing events, given ongoing R&D intensity and lack of revenue. Absent new capital, continued operating losses and burn could pressure liquidity if milestones slip or enrollment slows.